Press Releases Press Releases Year None202120202019201820172016201520142013201120102009200820072005 April 12, 2021 Intra-Cellular Therapies Presents Data on Antitumor Effects of Phosphodiesterase I Inhibition in a Preclinical Colorectal Cancer Model at the 2021 American Association for Cancer Research (AACR) Annual Meeting PDF Version February 25, 2021 Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2020 Financial Results And Provides Corporate Update PDF Version February 24, 2021 Intra-Cellular Therapies Announces Expansion of its Pipeline with the Introduction of a New Molecular Entity, ITI-1284 PDF Version February 22, 2021 Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression PDF Version February 19, 2021 Intra-Cellular Therapies to Present at the SVB Leerink 10th Annual Global Healthcare Conference PDF Version February 17, 2021 Intra-Cellular Therapies to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call and Webcast PDF Version January 21, 2021 CAPLYTA® (lumateperone) Open-Label Safety Switching Study in Patients with Schizophrenia Published in the Journal, Schizophrenia Research PDF Version January 5, 2021 Intra-Cellular Therapies to Present at the 39th Annual J.P. Morgan Healthcare Conference PDF Version
April 12, 2021 Intra-Cellular Therapies Presents Data on Antitumor Effects of Phosphodiesterase I Inhibition in a Preclinical Colorectal Cancer Model at the 2021 American Association for Cancer Research (AACR) Annual Meeting PDF Version
February 25, 2021 Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2020 Financial Results And Provides Corporate Update PDF Version
February 24, 2021 Intra-Cellular Therapies Announces Expansion of its Pipeline with the Introduction of a New Molecular Entity, ITI-1284 PDF Version
February 22, 2021 Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression PDF Version
February 19, 2021 Intra-Cellular Therapies to Present at the SVB Leerink 10th Annual Global Healthcare Conference PDF Version
February 17, 2021 Intra-Cellular Therapies to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call and Webcast PDF Version
January 21, 2021 CAPLYTA® (lumateperone) Open-Label Safety Switching Study in Patients with Schizophrenia Published in the Journal, Schizophrenia Research PDF Version
January 5, 2021 Intra-Cellular Therapies to Present at the 39th Annual J.P. Morgan Healthcare Conference PDF Version
